28 Nov 2017securities registration● Neutral
GB SCIENCES INC filed notice of an exempt private placement.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
20 Nov 2017quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $291 thousand and a net loss of $3.1 million for the period ended 2017-09-30.
7 Nov 2017late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its quarterly report would be filed late.
14 Aug 2017quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $69 thousand and a net loss of $3.1 million for the period ended 2017-06-30.
8 Aug 2017agm notice● Neutral
GB SCIENCES INC shareholders approved the routine matters put to a vote at the company's annual meeting (director elections, auditor ratification, and the executive-pay advisory vote).
7 Aug 2017director interest notice● Neutral
GB SCIENCES INC insider Craig Ellins sold 100,000 shares.
1 Aug 2017agm notice● Neutral
GB SCIENCES INC shareholders approved the routine matters put to a vote at the company's annual meeting (director elections, auditor ratification, and the executive-pay advisory vote).
27 June 2017late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its annual report would be filed late.
22 June 2017auditor change● Neutral
On June 21, 2017 the company retained Soles, Heyn & Company, LLP as auditor because its previous auditor, Patrick D. Heyn, CPA, merged into that firm. There was no resignation or dismissal, so this is an administrative change.
16 June 2017director interest notice● Neutral
Craig Ellins became a GB SCIENCES INC CEO and company insider (initial ownership filing).
16 June 2017director interest notice● Neutral
GB SCIENCES INC Chief Innovation Officer Craig Ellins sold 772,722 shares.
31 May 2017substantial holder notice● Neutral
Lazarus Management Company LLC, Justin B. Borus, Lazarus Investment Partners LLLP, Lazarus Israel Opportunities Fund LLLP reported a GB SCIENCES INC shareholding of 4,111,746 shares (3.70% of votes) in a periodic institutional filing.
16 Feb 2017material agreement● Neutral
The $0.20 warrant repricing announced January 31, 2017 was extended from 10 business days to run through February 28, 2017. Nothing else changed in this amendment.
14 Feb 2017quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $3.5 million for the period ended 2016-12-31.
8 Feb 2017substantial holder notice● Neutral
Lazarus Management Company LLC, Justin B. Borus, Lazarus Investment Partners LLLP, Lazarus Israel Opportunities Fund LLLP reported a GB SCIENCES INC shareholding of 7,111,746 shares (7.10% of votes) in a periodic institutional filing.
31 Jan 2017capital raising announcement● NeutralMajor
Effective January 25, 2017 the company temporarily cut the exercise price on certain existing warrants to $0.20 per share, down from $0.50 and $0.60, and 7,086,000 shares were issued to four holders at that price (about $1.42 million, which is arithmetic from the filing's figures). This adds shares and cash, and follows the company's earlier warrant repricings.
18 Nov 2016substantial holder notice● Neutral
Lazarus Management Company LLC, Justin B. Borus, Lazarus Investment Partners LLLP, Lazarus Israel Opportunities Fund LLLP reported a GB SCIENCES INC shareholding of 8,000,000 shares (8.60% of votes) in a periodic institutional filing.
14 Nov 2016quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $2.5 million for the period ended 2016-09-30.
14 Oct 2016agm notice● Neutral
GB SCIENCES INC shareholders approved the routine matters put to a vote at the company's annual meeting (director elections, auditor ratification, and the executive-pay advisory vote).
12 Oct 2016substantial holder notice● Neutral
Lazarus Management Company LLC, Justin B. Borus, Lazarus Investment Partners LLLP, Lazarus Israel Opportunities Fund LLLP reported a GB SCIENCES INC shareholding of 8,000,000 shares (10.60% of votes) in a periodic institutional filing.
12 Oct 2016director interest notice● Neutral
GB SCIENCES INC 10%+ owner Lazarus Management CO LLC sold 506,479 shares at $0.30.
7 Oct 2016substantial holder notice● Neutral
Lazarus Management Company LLC, Justin B. Borus, Lazarus Investment Partners LLLP, Lazarus Israel Opportunities Fund LLLP reported a GB SCIENCES INC shareholding of 7,906,749 shares (10.50% of votes) in a periodic institutional filing.
6 Oct 2016director interest notice● Neutral
GB SCIENCES INC 10%+ owner Lazarus Management CO LLC sold 785,000 shares.
13 Sept 2016substantial holder notice● Neutral
Lazarus Management Company LLC, Justin B. Borus, Lazarus Investment Partners LLLP, Lazarus Israel Opportunities Fund LLLP reported a GB SCIENCES INC shareholding of 8,691,479 shares (11.50% of votes) in a periodic institutional filing.
9 Sept 2016capital raising announcement● NeutralMajor
Since its last quarterly report the company sold 7,097,000 units at $0.20 each to 21 buyers, raising $1,419,400. Each unit is one share plus a five-year warrant at $0.60, so existing holders are diluted. Ksenia Griswold now signs as CFO.
What it means for a shareholder
7.1m new shares at US$0.200 to raise about US$1.4m. That's 11% dilution: every existing holder's slice gets 11% smaller. If you held US$1,000 of shares (5,000 at the issue price), your slice goes from 0.0087% to 0.00775% of the company. To keep it you'd need 618 more shares - about US$124 at the issue price.
Create a free account to see this worked out for your own holding.
26 Aug 2016agm notice● Neutral
GB SCIENCES INC shareholders approved the routine matters put to a vote at the company's annual meeting (director elections, auditor ratification, and the executive-pay advisory vote).
19 Aug 2016substantial holder notice● Neutral
Lazarus Management Company LLC, Justin B. Borus, Lazarus Investment Partners LLLP, Lazarus Israel Opportunities Fund LLLP reported a GB SCIENCES INC shareholding of 8,691,479 shares (12.70% of votes) in a periodic institutional filing.
15 Aug 2016quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $1.3 million for the period ended 2016-06-30.
12 Aug 2016agm notice● Neutral
GB SCIENCES INC shareholders approved the routine matters put to a vote at the company's annual meeting (director elections, auditor ratification, and the executive-pay advisory vote).
18 July 2016substantial holder notice● Neutral
Lazarus Management Company LLC, Justin B. Borus, Lazarus Investment Partners LLLP, Lazarus Israel Opportunities Fund LLLP reported a GB SCIENCES INC shareholding of 8,691,479 shares (14.10% of votes) in a periodic institutional filing.